![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » The Medicines Company Wins Appeal Against Hospira
The Medicines Company Wins Appeal Against Hospira
November 19, 2015
The Medicines Company has won a new review of its months-long court battle with Hospira over patents for its anticlotting drug Angiomax.
The U.S. Court of Appeals for the Federal Circuit agreed to give the case a fresh look, vacating an earlier panel decision that went against The Medicines Company, according to a Nov. 13 order.
That decision upheld a lower court decision to strip The Medicines Company of two patents for Angiomax (bivalirudin), a move that would enable Hospira to pursue a generic version of the drug.
Chief Judge Sharon Prost wrote in the order that the panelists should not have upheld the March 2014 district court ruling, stating that the district judge “clearly erred in finding that the claimed invention was not commercially offered for sale before the critical date. … Accordingly, we hold the asserted claims invalid.”
Upcoming Events
-
21Oct